



**BIO-PATH HOLDINGS TO ANNOUNCE SECOND QUARTER 2016 FINANCIAL RESULTS
ON AUGUST 10, 2016**

HOUSTON—August 3, 2016 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, August 10, 2016 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2016, and to provide a business overview.

To access the live conference call, please call (844) 260-6671 (domestic) or (508) 915-0912 (international) at least five minutes prior to the start time, and refer to conference ID 52615237. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path's second drug candidate, also a liposomal antisense drug, is being readied for the clinic where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at <http://www.biopathholdings.com>.

###

Contact Information:

Investors

Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369